Co-create the latest biotechnology products with Lithuanian companies!
Biotechnology is one of Lithuania’s fastest-growing sectors, with a growth rate significantly above the European average. Lithuania leads the EU in terms of the proportion of young people with higher education, and the science sector is expanding faster than almost anywhere else in Europe, with growth of 22% and 40 new startups entering the field in 2020. Lithuania’s goal is to achieve more than 500 startups, with a combined turnover of 3-4 billion, before 2030.
This Sector exports 85% of its production to foreign markets. TOP export markets are the USA, the Netherlands, Israel, Latvia, and Japan.
Highly qualified specialists
Highly innovative companies
Growing life sciences startup ecosystem
Strong international businesses
Support from government
The world has radically changed within just one year. The COVID-19 pandemic pushed countries to cooperate closer than ever before, yet there is still plenty of room for improvement. The whole world right now has one common enemy. Countries can – and must – work together to fight it.
In the past year, due to the recent pandemic, the biotechnology sector has made some profound advancements. What is fascinating is that the development of the sector will not only affect how we treat viruses but also how we treat other diseases, such as cancer, autoimmune and common infectious diseases. That is where new gene therapies could be useful.
Biotechnology had become one of the fastest-growing sectors in the world. The development of biotech promises to not only transform how we treat viruses, but also how we cure other illnesses such as cancer, autoimmune and infectious diseases. This is where the new gene therapy – a area in which both Germany and Lithuania enjoy competitive advantage – could come in handy.
The Covid-19 pandemic has turbo-charged the biotechnology sector. What is particularly fascinating is that the development of this sector will not only affect how we treat viruses but also how other diseases such as cancer are tackled. Several Lithuanian companies, notably CasZyme or Droplet Genomics, are ready to step in and help advance global healthcare, while making the country a life sciences hub.
Scientists are currently working to improve microfluidic technology. Their aims are to make it cheaper and more accessible for researchers, the pharmaceutical industry, and doctors diagnosing complex diseases. One of these companies pioneering microfluidic technology is Droplet Genomics, a Lithuanian company founded in 2016.